13143-47-0

Basic information

• Product Name: 1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE
• Synonyms: 1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE;1-(4-AMINOPHENYL)PYRIDIN-2(1H)-ONE;1-(4-aMino-phenyl)-1h-pyridine-2-one;1-(4-aminophenyl)-2(1H)-Pyridinone;Ethyl 7-chloro-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxylate;1-(4-Aminophenyl)
• CAS NO: 13143-47-0
• Molecular Formula: C₁₁H₁₀N₂O
• Molecular Weight: 186.2099
• Mol File: 13143-47-0.mol

Chemical Properties

• Boiling Point: 422.666 °C at 760 mmHg
• Flash Point: 209.421 °C
• Appearance: /
• Density: 1.266 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.89±0.10(Predicted)
• CAS DataBase Reference: 1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE(13143-47-0)
• EPA Substance Registry System: 1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE(13143-47-0)

Safety Data

• Hazardous Substances Data: 13143-47-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE is used as a synthetic intermediate for the development of novel 2,3-dihydroquinazolin-4(1H)-one derivatives. These derivatives have potential applications as inhibitors of factor Xa (fXa), which is a crucial enzyme in the coagulation cascade. Inhibiting fXa can help in the treatment and prevention of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism.
Additionally, 1-(4-AMINO-PHENYL)-1H-PYRIDIN-2-ONE may also be utilized in the synthesis of other bioactive molecules with potential applications in various therapeutic areas, such as anti-inflammatory, anti-cancer, and anti-microbial agents. Its versatility in chemical reactions and ability to form diverse molecular frameworks make it a valuable compound in the field of medicinal chemistry and drug discovery.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 142-08-5 2-Pyridone 
• 142-08-5 2-hydroxypyridin 
• 540-37-4 p-aminoiodobenzene 
• 53427-97-7 1-(4-nitrophenyl)pyridin-2(1H)-one 

Downstream Products

• 913742-47-9 5-chloro-thiophene-2-carboxylic acid ((R)-1-(2-[4-(2-oxo-pyridin-1-yl)-phenylamino]-acetyl)-pyrrolidin-3-yl)amide 
• 1187890-37-4 N-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-malonamic acid ethyl ester 
• 850003-11-1 (7R,7aR)-7-amino-2-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-hexahydro-pyrrolo[1,2-c]imidazol-3-one 
• 850003-09-7 (7S,7aR)-7-hydroxy-2-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-hexahydro-pyrrolo[1,2-c]imidazol-3-one 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors

Coagulation factor Xa (fXa) is a particularly attractive target for the development of effective and safe anticoagulants. In this study, novel 2,3-dihydroquinazolin-4(1H)-one derivatives were designed as potential fXa inhibitors based on anthranilamide structure which has been reported in our previous research. The experimental data showed that most of the designed compounds exhibited significant in?vitro potency against fXa. Among them, compound 8e displayed the strongest potency against fXa with the IC50value of 21?nM and highly selectivity versus thrombin (IC50?=?67?μM) and excellent in?vitro antithrombotic activity with its 2?×?PT value of 1.2?μM and 2?×?aPTT value of 0.6?μM. In addition, 8e also displayed excellent in?vivo antithrombotic activity in the rat arteriovenous shunt (AV-SHUNT) model. The bleeding risk evaluation showed that 8e had a similar safety profile as that of betrixaban. All results demonstrated that compound 8e could be considered as a potential fXa inhibitor for the prevention and treatment of thromboembolic diseases.

Preparation method for 1-(4-aminophenyl)-1H-pyridin-2-one

The invention relates to a preparation method for 1-(4-aminophenyl)-1H-pyridin-2-one. The preparation method comprises the steps that reflux reaction is carried out on paraiodoaniline and 2-hydroxypyridine under the presence of 8-hydroxyquinoline, potassi

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other

ANTIVIRAL COMPOUNDS

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection.

NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF

Provided are novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of F

NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE

The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R1, R2, R3, R4, R5, X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

UREAS AS FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.